@maddieshae23's GLP-1 video claims need fact-checking

What did @maddieshae23 actually say?

She's promoting a telehealth provider, linked in her bio, that offers GLP-1 medications without membership fees, doctor fees, or shipping costs. Her pitch: fill out a health assessment, meet a BMI of 28 or above, get doctor approval, and receive medication at home in five to seven days. "Super simple, super easy," she says, and she's available for questions. This is, functionally, an advertisement, though it isn't labeled as one.

To be fair, she doesn't make outrageous medical claims about what the drugs will do. She doesn't promise a specific amount of weight loss or call anything a cure. What she does do is make the prescribing process sound frictionless, which deserves a harder look than 620,000 viewers probably gave it.

Does the science back this up?

The clinical evidence for semaglutide and tirzepatide is genuinely strong, so the underlying drugs aren't the problem here. The problem is the process she's describing.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide producing up to 20.9% mean body weight reduction over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4mg producing around 14.9% weight loss. These are meaningful results. But both trials involved careful screening, monitoring of heart rate, thyroid history, pancreatitis risk, and regular follow-up, none of which she mentions.

A BMI of 28 as a standalone eligibility criterion is lower than FDA-approved labeling. Wegovy and Zepbound are approved for BMI of 30 or above, or 27 with a weight-related comorbidity. A telehealth platform using 28 as the floor without mentioning comorbidities is already operating at the edge of standard prescribing guidelines.

What did they get wrong (or right)?

She gets credit for one thing: she's correct that many telehealth platforms do charge layered fees, and that the cost and friction of accessing GLP-1s is a real barrier for patients. That's a legitimate point.

But she gets a few things meaningfully wrong. First, a "quick health assessment" is not equivalent to a clinical evaluation. GLP-1 agonists carry real contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a history of pancreatitis, among others. A checkbox form does not catch these reliably.

Second, describing this as "your journey" while linking to a provider in her bio, with no disclosure of a financial relationship, raises FTC compliance questions. The FTC's 2023 guidance on endorsements requires clear disclosure when there's a material connection to a brand. That disclosure is absent here.

Third, compounded GLP-1 medications, which is almost certainly what this provider is offering given the pricing model, are not FDA-approved drugs. They are not equivalent to brand-name Wegovy or Zepbound. The FDA has repeatedly warned about quality and dosing variability in compounded semaglutide and tirzepatide (FDA Drug Safety Communications, 2023-2024).

What should you actually know?

If you're considering a GLP-1 medication through any telehealth platform, the absence of fees is not the most important factor. What matters is whether the provider is actually reviewing your full medical history, not just a short intake form.

Ask specifically whether the medication being offered is FDA-approved or compounded. Ask what follow-up looks like after you receive the medication. Ask whether a real licensed clinician, not just an algorithm, reviews your intake. The American Association of Clinical Endocrinology recommends ongoing monitoring for heart rate changes, gastrointestinal symptoms, and thyroid nodules in patients on GLP-1 therapy (AACE Clinical Practice Guideline, 2023).

The five-to-seven-day delivery window she cites may be accurate for some compounders, but speed of delivery is not a proxy for quality of care. If a provider is willing to ship a hormonal medication with significant cardiovascular and gastrointestinal effects to your door based on a form, ask yourself what happens when something goes wrong and who's actually responsible for your care at that point.